Loading ...Congressional Report: FDA Inappropriately “Collaborated” with Biogen
A House investigation has concluded that the Food and Drug Administration (FDA) “collaborated” with biotechnology company Biogen on the approval of its Alzheimer’s drug Aduhelm. Indeed, as 2022 comes to a close, American taxpayers are reminded yet again of the inappropriate and dishonest manner in which the FDA—the agency funded by taxpayers to ensure the safety and efficacy of the medications they take—collaborates with Big Pharma.
Eighteen months in the making, the just-released report titled “The High Price of Aduhelm’s Approval: An Investigation into FDA’s Atypical Review Process and Biogen’s Aggressive Launch Plans” found that the FDA’s approval process was “rife with irregularities.” The two House of Representatives committees—Oversight and Reform and Energy and Commerce—investigated the drug’s regulatory review, approval, pricing, and marketing. The report points to “collaboration” between Biogen and the FDA ahead of an advisory committee meeting that nevertheless resulted in none of the eleven panelists voting in favor of approval for Aduhelm (aducanumab).